Products
Sorafenib
Pharmacotherapeutic group
Antineoplastic agents; protein kinase inhibitors; other protein kinase inhibitorsInternational name
sorafenibDosage form
film-coated tabletsProduct information
Download Sorafenib.pdf (RU)
Go to the State Register of Medicinal Products site ➞
Sorafenib is a multikinase inhibitor. It reduces tumor cell proliferation in vitro.
Sorafenib has been shown to inhibit numerous intracellular kinases (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-β). Some of these kinases are believed to be involved in tumor cell signaling systems, angiogenesis and apoptosis.
Sorafenib suppresses tumor growth in liver-cell, renal-cell cancer, differentiated thyroid cancer in humans.
Sorafenib has been shown to inhibit numerous intracellular kinases (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-β). Some of these kinases are believed to be involved in tumor cell signaling systems, angiogenesis and apoptosis.
Sorafenib suppresses tumor growth in liver-cell, renal-cell cancer, differentiated thyroid cancer in humans.